All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2017-03-14T12:23:05.000Z

The FDA grants FATE-NK100 Investigational New Drug Application clearance for treatment of R/R AML

Mar 14, 2017
Share:

Bookmark this article

On 13th March 2017, the U.S. Food and Drug Administration (FDA) granted Investigational New Drug (IND) application clearance for FATE-NK100, a first-in-class adaptive Natural Killer (NK) cell, for the treatment of patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML).1

FATE-NK100 is comprised of a highly specialized and functionally distinct subset of NK cells expressing the memory-like activating receptor NKG2C and the maturation marker CD57. In AML, NK cells have been shown to exert powerful anti-leukemic activity in preventing relapse.2 Preclinical data have demonstrated that FATE-NK100 can induce a robust formation of adaptive memory NK cells which have an enhanced anti-tumor activity and improved persistence. Additionally, FATE-NK100 have been shown to stimulate an endogenous T-cell response and also resist immune checkpoints. 1,3

The IND approval granted by the FDA allows FATE-NK100 to be evaluated in a first-in-human trial in R/R AML patients. This study will evaluate the safety and determine the maximum dose of intravenous infusion of FATE-NK100 in R/R patients. Additionally, Complete Response (CR), Disease Free Survival (DFS), and clearance of Minimal Residual Disease (MRD) would also be accessed secondarily. Enrollment into trials are anticipated to start at the Masonic Cancer Center, University of Minnesota, following approval of the Center’s institutional review board.1

  1. GlobeNewswire: Fate Therapeutics Announces FDA Clearance of Investigational New Drug Application for FATE-NK100 Natural Killer Cell Cancer Immunotherapy. 2017 Mar 13. https://globenewswire.com/news-release/2017/03/13/934947/0/en/Fate-Therapeutics-Announces-FDA-Clearance-of-Investigational-New-Drug-Application-for-FATE-NK100-Natural-Killer-Cell-Cancer-Immunotherapy.html [Accessed 2017 Mar 14].
  2. Suck G.et al. Natural Killer Cells for Therapy of Leukemia. Transfus Med Hemother. 2016 Mar; 43(2): 89–95. DOI: 1159/000445325.
  3. Cichocki F. et al. Development and Scale-up of a Novel GMP Method for Enrichment and Expansion of Terminally Differentiated Adaptive Natural Killer Cells (FATE-NK100) with Enhanced Anti-Tumor Function. 2016 December 5; Oral Abstract #1225: ASH 58th Annual Meeting and Exposition, San Diego, CA.
More about...

Your opinion matters

Do you intend to implement next generation sequencing for measurable residual disease monitoring in AML patients?
0 votes - 6 days left ...

Newsletter

Subscribe to get the best content related to AML delivered to your inbox